blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2841456

EP2841456 - HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.04.2019
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  11.05.2018
FormerGrant of patent is intended
Status updated on  20.12.2017
FormerExamination is in progress
Status updated on  03.03.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Novo Nordisk A/S
Novo Allé
2880 Bagsværd / DK
For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799 / US
[2018/24]
Former [2015/10]For all designated states
Novo Nordisk A/S
Novo Allé
2880 Bagsværd / DK
For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799 / US
Inventor(s)01 / ANDERSEN, Mette, Dahl
c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd / DK
02 / DANTZLER, Jeff
14012 Wayne Pl. N.
Seattle, WA 98133 / US
03 / ARMITAGE, Richard, J.
5840 Packard Lane
Bainbridge Island, WA 98110 / US
04 / CLARK, Rutilio
5335 Old Mill Road NE
Bainbridge Island, WA 98110 / US
 [2015/10]
Representative(s)EIP
Fairfax House
15 Fulwood Place
London WC1V 6HU / GB
[N/P]
Former [2018/24]EIP
EIP Europe LLP
Fairfax House
15 Fulwood Place
London WC1V 6HU / GB
Former [2015/10]Petersen, Birgit Otzen, et al
Novo Nordisk A/S
Corporate Patents
Novo Allé
2880 Bagsværd / DK
Application number, filing date13720714.825.04.2013
[2018/24]
WO2013US38135
Priority number, dateUS201261639637P27.04.2012         Original published format: US 201261639637 P
[2015/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013163377
Date:31.10.2013
Language:EN
[2013/44]
Type: A1 Application with search report 
No.:EP2841456
Date:04.03.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 31.10.2013 takes the place of the publication of the European patent application.
[2015/10]
Type: B1 Patent specification 
No.:EP2841456
Date:13.06.2018
Language:EN
[2018/24]
Search report(s)International search report - published on:EP31.10.2013
ClassificationIPC:C07K16/28
[2015/10]
CPC:
C07K16/2875 (EP,IL,RU,US); A61K39/3955 (RU); C07K16/28 (KR);
A61K39/395 (KR); A61P13/12 (EP,IL); A61P17/00 (EP,IL);
A61P19/02 (EP,IL); A61P19/06 (EP,IL); A61P21/00 (EP,IL);
A61P25/00 (EP,IL); A61P27/02 (EP,IL); A61P29/00 (EP,IL);
A61P3/04 (EP,IL); A61P3/10 (EP,IL); A61P35/00 (EP,IL);
A61P35/02 (EP,IL); A61P37/00 (EP,IL); A61P37/02 (EP,IL);
A61P37/06 (EP,IL); A61P43/00 (EP,IL); A61P5/16 (EP,IL);
A61P5/38 (EP,IL); C07K14/70575 (EP,IL,US); C07K16/2803 (KR);
A61K2039/505 (EP,IL,US); C07K2317/21 (EP,IL,US); C07K2317/34 (EP,IL,US);
C07K2317/55 (EP,IL,US); C07K2317/565 (IL,US); C07K2317/732 (EP,IL,US);
C07K2317/76 (EP,IL,US); C07K2317/92 (EP,IL,US); C07K2319/21 (EP,IL,US);
C07K2319/43 (EP,IL,US); C07K2319/50 (EP,IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/10]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:HUMANE CD30 LIGAND ANTIGEN BINDENDE PROTEINE[2018/02]
English:HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS[2015/10]
French:PROTÉINES DE LIAISON AU LIGAND DE CD30 HUMAINE[2018/02]
Former [2015/10]MENSCHLICHES CD30-LIGANDANTIGEN BINDENDE PROTEINE
Former [2015/10]PROTÉINES DE LIAISON À L'ANTIGÈNE LIGAND CD30 HUMAIN
Entry into regional phase27.11.2014National basic fee paid 
27.11.2014Designation fee(s) paid 
27.11.2014Examination fee paid 
Examination procedure27.11.2014Examination requested  [2015/10]
18.06.2015Amendment by applicant (claims and/or description)
10.03.2017Despatch of a communication from the examining division (Time limit: M06)
20.09.2017Reply to a communication from the examining division
04.10.2017Despatch of a communication from the examining division (Time limit: M02)
30.11.2017Reply to a communication from the examining division
21.12.2017Communication of intention to grant the patent
27.04.2018Receipt of the translation of the claim(s)
30.04.2018Fee for grant paid
30.04.2018Fee for publishing/printing paid
Divisional application(s)EP18169942.2  / EP3431492
EP20207117.1  / EP3929208
EP22188601.3
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.03.2017
Opposition(s)14.03.2019No opposition filed within time limit [2019/21]
Fees paidRenewal fee
30.04.2015Renewal fee patent year 03
02.05.2016Renewal fee patent year 04
02.05.2017Renewal fee patent year 05
27.04.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL13.06.2018
CY13.06.2018
EE13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
MK13.06.2018
MT13.06.2018
RS13.06.2018
SM13.06.2018
IS13.10.2018
[2022/31]
Former [2021/34]AL13.06.2018
CY13.06.2018
EE13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
MT13.06.2018
RS13.06.2018
SM13.06.2018
IS13.10.2018
Former [2020/02]AL13.06.2018
CY13.06.2018
EE13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
MC13.06.2018
RS13.06.2018
SM13.06.2018
IS13.10.2018
Former [2019/51]AL13.06.2018
CY13.06.2018
EE13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
SM13.06.2018
IS13.10.2018
Former [2019/12]CY13.06.2018
EE13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
SM13.06.2018
IS13.10.2018
Former [2019/09]CY13.06.2018
EE13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
IS13.10.2018
Former [2019/08]CY13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
IS13.10.2018
Former [2018/51]CY13.06.2018
HR13.06.2018
LT13.06.2018
LV13.06.2018
RS13.06.2018
Former [2018/50]CY13.06.2018
HR13.06.2018
LT13.06.2018
Former [2018/47]LT13.06.2018
Cited inInternational search[A]WO9324135  (IMMUNEX CORP [US]);
 [I]WO0211767  (IMMUNEX CORP [US], et al);
by applicantUS4399216
 WO8705330
 WO8801649
 US4740461
 US4751180
 US4816567
 US4912040
 WO9004036
 EP0367566
 US4935233
 US4946778
 US4959455
 US4965195
 US4968607
 US5011912
 WO9110741
 EP0460846
 WO9203918
 WO9222646
 WO9301227
 WO9310151
 EP0546073
 US5260203
 US5262522
 WO9402602
 WO9410308
 US5426048
 US5457035
 US5480981
 US5530101
 US5545807
 US5545806
 US5569825
 WO9633735
 US5585089
 US5625126
 US5633425
 US5661016
 EP0546073
 US5677430
 US5693762
 US5693761
 WO9824893
 US5770429
 US5789650
 US5814318
 US5874299
 US5877397
 WO9910494
 WO0009560
 US6143869
 US6162963
 US6180370
 US6255458
 US6270964
 US6300129
 US6652854
 US6667039
 US6673986
 US6713610
 US6946292
 US7425446
 US7846725
 US8067232
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.